TARSUS PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
TARSUS PHARMACEUTICALS, INC. (TARS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $10.21 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-23
- TARSUS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- TARSUS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $10.21M.
- TARSUS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- TARSUS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $10.21M, a 2558.59% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $384.00K, a 79.20% decline from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.85M.
- TARSUS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 1 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $10.21M derived: sum of 2 quarters · filed 2026-02-23 | $10.21M derived: sum of 3 quarters · filed 2026-02-23 | $10.21M 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $10.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $10.21M derived: sum of 2 quarters · filed 2025-11-04 | $10.21M 10-Q · filed 2025-11-04 | $10.21M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $384.00K 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $384.00K 10-Q · filed 2025-11-04 | $384.00K derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $384.00K 10-Q · filed 2025-08-06 | $384.00K derived: sum of 3 quarters · filed 2026-02-23 | $384.00K derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-03-31 | $400.00K 10-K · filed 2025-02-25 | $384.00K 10-Q · filed 2025-05-01 | $384.00K derived: sum of 2 quarters · filed 2026-02-23 | $384.00K derived: sum of 3 quarters · filed 2026-02-23 | $2.11M derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2024-03-20 | $400.00K 10-Q · filed 2024-08-08 | ||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $1.73M derived: sum of 3 quarters · filed 2026-02-23 | $1.85M 10-K · filed 2026-02-23 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.73M derived: sum of 2 quarters · filed 2024-11-13 | $1.85M 10-Q · filed 2024-11-13 | $1.85M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.85M 10-Q · filed 2024-08-08 | $1.85M derived: sum of 3 quarters · filed 2025-02-25 | $1.85M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | $116.00K 10-Q · filed 2024-05-08 | $116.00K derived: sum of 2 quarters · filed 2025-02-25 | $116.00K derived: sum of 3 quarters · filed 2025-02-25 | $116.00K derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2023-08-10 | $741.00K derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-05-09 | $741.00K derived: sum of 3 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $741.00K derived: sum of 2 quarters · filed 2023-03-17 | $741.00K 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | $741.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $741.00K 10-Q · filed 2022-11-09 | |||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$41.00K derived: sum of 2 quarters · filed 2022-03-14 | $726.00K 10-K · filed 2022-03-14 | ||||
| 2020-09-30 | -$41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $726.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $767.00K 10-Q · filed 2021-08-05 | ||||||
| 2020-06-01 | $600.00K 10-Q · filed 2021-08-05 | $700.00K 10-Q · filed 2020-11-25 | |||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $163.00K 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | $163.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |